Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
20 June 2013Website:
http://www.ptcbio.comNext earnings report:
25 October 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 30 Sep 2024 21:38:34 GMTDividend
Analysts recommendations
Institutional Ownership
PTCT Latest News
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Ron Aldridge – Senior Director of Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Kylie O'Keefe - Chief Commercial Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Eric Joseph – J.P. Morgan Kelly Shi – Jefferies Samantha Corwin - William Blair Brian Abraham - RBC Capital Markets Joseph Thome - TD Cowen Jeff Hung - Morgan Stanley Gena Wang – Barclays David Lebowitz – Citi Joseph Schwartz - Leerink Partners Operator Good day and thank you for standing by.
PTC Therapeutics (PTCT) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $2.66 per share a year ago.
NEW YORK CITY, NY / ACCESSWIRE / July 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
NEW YORK CITY, NY / ACCESSWIRE / July 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQ: PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
NEW YORK CITY, NY / ACCESSWIRE / July 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
NEW YORK CITY, NY / ACCESSWIRE / July 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
NEW YORK CITY, NY / ACCESSWIRE / July 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQ: PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. (“PTC” or “the Company”) (NASDAQ: PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PTCT.
What type of business is PTC Therapeutics?
PTC Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of drugs for the treatment of rare diseases. PTC Therapeutics, Inc. was founded in 1998, with its headquarters located in South Plainfield, New Jersey. PTC Therapeutics offers products such as Translarna and Emflaza for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; Tegsedi and Waylivra for the treatment of rare diseases in Latin American and Caribbean countries. The company is also developing a range of gene therapy candidates for the treatment of rare monogenic diseases affecting the central nervous system, including PTC-AADC for the treatment of a rare CNS disorder resulting from reduction.
What sector is PTC Therapeutics in?
PTC Therapeutics is in the Healthcare sector
What industry is PTC Therapeutics in?
PTC Therapeutics is in the Biotechnology industry
What country is PTC Therapeutics from?
PTC Therapeutics is headquartered in United States
When did PTC Therapeutics go public?
PTC Therapeutics initial public offering (IPO) was on 20 June 2013
What is PTC Therapeutics website?
https://www.ptcbio.com
Is PTC Therapeutics in the S&P 500?
No, PTC Therapeutics is not included in the S&P 500 index
Is PTC Therapeutics in the NASDAQ 100?
No, PTC Therapeutics is not included in the NASDAQ 100 index
Is PTC Therapeutics in the Dow Jones?
No, PTC Therapeutics is not included in the Dow Jones index
When was PTC Therapeutics the previous earnings report?
No data
When does PTC Therapeutics earnings report?
The next expected earnings date for PTC Therapeutics is 25 October 2024